Pittsburgh-based Predictive Oncology uses machine learning, human tumor data and laboratory models to support oncology drug discovery and clinical treatment decisions. Its proprietary platform draws on a privately held biobank of more than 150,000 tumor samples, while its CLIA-certified Helomics laboratory provides tumor drug-response and genomic testing alongside research support for biopharmaceutical developers.
CLIA-certified laboratory
Duo OncologyFounded by nanoparticle and drug-delivery researchers, Pittsburgh-based Duo Oncology is a clinical-stage biotechnology company developing tumor-activated medicines for cancer treatment. Its lead program, DUO-207, is designed to simplify chemotherapy by concentrating drug activity in tumors while reducing exposure in healthy tissue.PITTSBURGH, PA
MetasTx, LLCPittsburgh-based MetasTx, LLC is developing a precision-oncology platform that pairs a diagnostic for identifying prostate cancer patients at high risk of metastasis with next-generation KIT inhibitors intended to block cancer spread and treatment resistance. Its NCI-supported diagnostic study with Allegheny Health Network and licensed inhibitor compounds from the Crich UGARF laboratories connect clinical research with a targeted therapeutic program. The company’s leadership brings experience from institutions and oncology organizations including Merck and AstraZeneca.PITTSBURGH, PA
Facili Bio LLCFacili Bio LLC uses an AI-powered drug-discovery platform and proprietary computational biology to develop new cancer treatments. The company focuses on difficult areas of oncology, pairing research into patient-specific therapies with clinical studies intended to move promising discoveries toward patients.ALBANY, NY